Fig. 3From: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian settingResults of the probabilistic sensitivity analysis illustrated in a cost-effectiveness planeBack to article page